Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Randomized, Blinded, Placebo-Controlled Study Evaluating Nogapendekin Alfa Inbakicept and iNKT Cells In Critically Ill Adults With Severe Community-Acquired Pneumonia With or Without Sepsis/Acute Respiratory Distress Syndrome

NCT07492875 is registered in ClinicalTrials.gov with ImmunityBio, Inc. as lead sponsor.

NCT NCT07492875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07492875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Randomized, Blinded, Placebo-Controlled Study Evaluating Nogapendekin Alfa Inbakicept and iNKT Cells In Critically Ill Adults With Severe Community-Acquired Pneumonia With or Without Sepsis/Acute Respiratory Distress Syndrome
Lead sponsor
ImmunityBio, Inc.
Phase
Phase 3
Overall status
Withdrawn
Start date
April 15, 2026
Completion date
December 31, 2029
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute respiratory distress syndrome (ards), community-acquired pneumonia (cap), immunoparalysis, lymphopenia, sepsis